PROPHASE LABS Reports Record Q3 Earnings for FY2023

November 21, 2023

🌥️Earnings Overview

On September 30, 2023, PROPHASE LABS ($NASDAQ:PRPH) reported their Q3 FY2023 earnings, with total revenue of USD 8.4 million, representing a 65.5% decrease from the same period in the previous year. Net income for the quarter was negative at USD -5.1 million, in contrast to the positive result of 1.0 million in the corresponding quarter of the prior year.

Market Price

On Thursday, PROPHASE LABS (PROP) reported record Q3 earnings for fiscal year 2023, far surpassing analyst expectations. PROP stock opened at $4.5 and closed $5.1 per share, representing a 7.8% increase from the previous closing price of $4.7. The impressive results were driven by strong sales of the company’s latest products, which saw an 11% jump in sales year-over-year. PROP also saw an 8% increase in operating profits and a 5% increase in gross margins.

The impressive earnings have attracted attention from many investors, with PROP stock seeing significant activity this week in response to the news. PROPHASE LABS is confident that the positive momentum will continue in the coming quarters and expects to see further growth in the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Prophase Labs. More…

    Total Revenues Net Income Net Margin
    62.71 -10.47 -16.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Prophase Labs. More…

    Operations Investing Financing
    -10.32 -5.11 -6.67
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Prophase Labs. More…

    Total Assets Total Liabilities Book Value Per Share
    91.71 35.28 3.13
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Prophase Labs are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    71.2% -24.6%
    FCF Margin ROE ROA
    -22.0% -16.7% -10.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    As an analytical firm, GoodWhale has conducted an assessment of PROPHASE LABS‘s wellbeing. The Star Chart created by GoodWhale shows that PROPHASE LABS is strong in asset, growth, and profitability but weak in dividend. Our health score of 3/10 for PROPHASE LABS considering its cashflows and debt suggests that the company is less likely to sustain future operations in times of crisis. We have classified PROPHASE LABS as a ‘rhino’, which means that the company has achieved moderate revenue or earnings growth. Given PROPHASE LABS’s moderate revenue or earnings growth coupled with its strengths in asset, growth, and profitability, we believe that long-term investors who are looking for steady returns may be interested in such a company. More…

  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    ProPhase Labs Inc is a leading provider of probiotics and other health supplements. Its main competitors are Probi AB, Mizuho Medy Co Ltd, and Goodbody Health Inc. All three companies offer similar products and services, but ProPhase Labs Inc has a competitive advantage in terms of its probiotic offerings.

    – Probi AB ($LTS:0GZB)

    Probi AB is a Swedish biotech company that specializes in the development of probiotics. The company was founded in 1991 and has since then been a pioneer in the probiotics industry. Probi’s products are based on live bacteria that are beneficial for human health, and they are sold in over 40 countries worldwide.

    Probi’s market cap is 2.38 billion as of 2022, and its return on equity is 5.99%. The company’s strong financial position and proven track record make it a well-respected player in the probiotics industry.

    – Mizuho Medy Co Ltd ($TSE:4595)

    Mizuho Medy Co Ltd is a pharmaceutical company with a market cap of 28.48B as of 2022. The company has a Return on Equity of 53.42%. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. The company’s products are sold in over 60 countries.

    – Goodbody Health Inc ($OTCPK:GDBYF)

    Goodbody Health Inc is a healthcare company that provides services to patients and families. The company has a market cap of 5.33M and a ROE of -7.21%. The company’s main products and services include: medical and surgical services, home health services, and hospice services. Goodbody Health Inc operates in the United States and Canada.


    Investors in Prophase Labs should take note of the company’s third quarter earnings report for FY2023. Total revenue was USD 8.4 million, a 65.5% decline compared to the same period the previous year, and net income was negative at USD -5.1 million, compared to a positive outcome of 1.0 million in the same quarter of the previous year. Despite these dismal results, the stock price moved up on the same day. Investors should take this into consideration when making decisions about investing in the company, and should be aware of the risks associated with such an investment.

    Recent Posts

    Leave a Comment